Publications
84 results found
Best L, Ghadery C, Pavese N, et al., 2019, New and Old TSPO PET Radioligands for Imaging Brain Microglial Activation in Neurodegenerative Disease, CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, Vol: 19, ISSN: 1528-4042
- Author Web Link
- Cite
- Citations: 47
Amara AW, Chahine L, Seedorff N, et al., 2019, Self-reported physical activity levels and clinical progression in early Parkinson's disease, PARKINSONISM & RELATED DISORDERS, Vol: 61, Pages: 118-125, ISSN: 1353-8020
- Author Web Link
- Cite
- Citations: 38
Mousele C, Bentley P, Tai YF, 2018, A rare presentation of orthostatic tremor as abdominal tremor, Tremor and Other Hyperkinetic Movements, Vol: 8, ISSN: 2160-8288
Background: Orthostatic tremor (OT) is a weight-bearing hyperkinetic disorder characterized by unsteadiness while standing that is relieved when sitting or walking.Case report: A 66-year-old male presented with a 5 year-history of tremor in his abdomen, but only when he stood in a stationary position. The tremor disappeared when he stood or walked. On examination, he had palpable tremor in his rectus abdominis and gastrocnemius virtually instantaneously after standing. His electromyography findings confirmed the presence of a 12-Hz tremor in the tibialis anterior while standing, with subharmonics recorded in the external obliques and rectus abdominis.Discussion: Our case illustrates an unusual presentation of OT. The diagnosis is supported by its characteristic frequency and specific appearance only during upright stance.
Maxan A, Mason S, Saint-Pierre M, et al., 2018, Outcome of cell suspension allografts in a patient with Huntington's disease, Annals of Neurology, Vol: 84, Pages: 950-956, ISSN: 0364-5134
For patients with incurable neurodegenerative disorders such as Huntington's (HD) and Parkinson's disease, cell transplantation has been explored as a potential treatment option. Here, we present the first clinicopathological study of a patient with HD in receipt of cell-suspension striatal allografts who took part in the NEST-UK multicenter clinical transplantation trial. Using various immunohistochemical techniques, we found a discrepancy in the survival of grafted projection neurons with respect to grafted interneurons as well as major ongoing inflammatory and immune responses to the grafted tissue with evidence of mutant huntingtin aggregates within the transplant area. Our results indicate that grafts can survive more than a decade post-transplantation, but show compromised survival with inflammation and mutant protein being observed within the transplant site. Ann Neurol 2018; 1-7.
Marek K, Chowdhury S, Siderowf A, et al., 2018, The Parkinson's progression markers initiative (PPMI) - establishing a PD biomarker cohort, Annals of Clinical and Translational Neurology, Vol: 5, Pages: 1460-1477, ISSN: 2328-9503
ObjectiveThe Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker-defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease (PD) progression markers to accelerate disease-modifying therapeutic trials.MethodsA total of 423 untreated PD, 196 Healthy Control (HC) and 64 SWEDD (scans without evidence of dopaminergic deficit) subjects were enrolled at 24 sites. To enroll PD subjects as early as possible following diagnosis, subjects were eligible with only asymmetric bradykinesia or tremor plus a dopamine transporter (DAT) binding deficit on SPECT imaging. Acquisition of data was standardized as detailed at www.ppmi-info.org.ResultsApproximately 9% of enrolled subjects had a single PD sign at baseline. DAT imaging excluded 16% of potential PD subjects with SWEDD. The total MDS-UPDRS for PD was 32.4 compared to 4.6 for HC and 28.2 for SWEDD. On average, PD subjects demonstrated 45% and 68% reduction in mean striatal and contralateral putamen Specific Binding Ratios (SBR), respectively. Cerebrospinal fluid (CSF) was acquired from >97% of all subjects. CSF (PD/HC/SWEDD pg/mL) α-synuclein (1845/2204/2141) was reduced in PD vs HC or SWEDD (P < 0.03). Similarly, t-tau (45/53) and p-tau (16/18) were reduced in PD versus HC (P < 0.01),InterpretationPPMI has detailed the biomarker signature for an early PD cohort defined by clinical features and imaging biomarkers. This strategy provides the framework to establish biomarker cohorts and to define longitudinal progression biomarkers to support future PD treatment trials.
Deuschl G, Jain R, Scholtes H, et al., 2018, Outcomes of a Prospective, Multicenter International Registry of Deep Brain Stimulation, 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0028-3878
Pavese N, Tai YF, 2018, Nigrosome imaging and neuromelanin sensitive MRI in diagnostic evaluation of parkinsonism, Movement Disorders Clinical Practice, ISSN: 2330-1619
Lao-Kaim NP, Piccini P, Tai YF, 2017, Restorative strategies in movement disorders: the contribution of imaging, Current Neurology and Neuroscience Reports, Vol: 17, ISSN: 1528-4042
Purpose of ReviewThe purpose of this review was to review the imaging, particularly positron emission tomography (PET), findings in neurorestoration studies in movement disorders, with specific focus on neural transplantation in Parkinson’s disease (PD) and Huntington’s disease (HD).Recent FindingsPET findings in PD transplantation studies have shown that graft survival as reflected by increases in dopaminergic PET markers does not necessarily correlate with clinical improvement. PD patients with more denervated ventral striatum and more imbalanced serotonin-to-dopamine ratio in the grafted neurons tended to have worse outcome. In HD transplantation studies, variable graft survival and clinical responses may be related to host inflammatory/immune responses to the grafts.SummaryInformation gleaned from imaging findings in previous neural transplantation studies has been used to refine study protocol and patient selection in future trials. This includes identifying suitable candidates for transplantation using imaging markers, employing multiple and/or novel PET tracers to better assess graft functions and inflammatory responses to grafts.
Angeles P, Tai Y, Pavese N, et al., 2017, Assessing Parkinson's disease motor symptoms using supervised learning algorithms, 21st International Congress of Parkinson's Disease and Movement Disorders, Publisher: WILEY, ISSN: 0885-3185
Angeles P, Tai Y, Pavese N, et al., 2017, Automated assessment of symptom severity changes during deep brain stimulation (DBS) therapy for Parkinson's disease., Publisher: Institute of Electrical and Electronics Engineers Inc., ISSN: 1945-7901
Tai YF, Pavese N, 2016, Big Data and Parkinson's Disease - from Understanding of Disease to Personalised Medicine, American Journal of Neuroscience, Vol: 7, Pages: 1-3, ISSN: 1948-9900
Pavese N, Tai Y, 2016, Genetic and degenerative disorders primarily causing other movement disorders, Handbook of Clinical Neurology - Neuroimaging Part 1, Editors: Masdeu, Gonzalez, Publisher: Elsevier, Pages: 507-523, ISBN: 978-0-444-53486-6
Wilkinson L, Tai YF, Lin CS, et al., 2014, Probabilistic Classification Learning With Corrective Feedback is Associated With in vivo Striatal Dopamine Release in the Ventral Striatum, While Learning Without Feedback is Not, HUMAN BRAIN MAPPING, Vol: 35, Pages: 5106-5115, ISSN: 1065-9471
- Author Web Link
- Open Access Link
- Cite
- Citations: 20
Tai YF, Pavese N, 2013, Dopamine Imaging in Idiopathic Parkinson disease and other Parkinsonisms, Neuroimaging of Movement Disorders, Editors: nahab, Hattori, Publisher: Springer Science & Business Media, Pages: 129-142, ISBN: 9781627034715
Neuroimaging of Movement Disorders is an indispensable reference that will be of value to all physicians and researchers involved in the care of patients with movement disorders.
Barker RA, Mason SL, Harrower TP, et al., 2013, The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 84, Pages: 657-665, ISSN: 0022-3050
- Author Web Link
- Open Access Link
- Cite
- Citations: 74
Rajakulendran S, Pathak S, Tai YF, et al., 2013, VZV uveoretino meningitis following dental treatment, JOURNAL OF NEUROVIROLOGY, Vol: 19, Pages: 188-189, ISSN: 1355-0284
Tai YF, Pavese N, 2013, Dopamine Imaging in Idiopathic Parkinson Disease and Other Parkinsonisms, Current Clinical Neurology, Vol: 44, Pages: 129-141, ISSN: 1559-0585
Parkinsonism is clinically characterised by slowed movement, muscle rigidity, tremor at rest and postural instability, along with a variety of non-motor features. Many of these findings are closely linked to the progressive loss of nigrostriatal dopamine neurons. Various methods have been developed to image dopamine in the brain. This chapter will review the various imaging methods and summarise the diagnostic utility of dopamine imaging in idiopathic Parkinson disease (iPD) and other related disorders. Discussion will also provide insights into future applications of dopamine imaging, including its use as a biomarker in clinical trials.
Tomasi G, Bertoldo A, Cobelli C, et al., 2011, Global-two-stage filtering of clinical PET parametric maps: Application to [<SUP>11</SUP>C]-(R)-PK11195, NEUROIMAGE, Vol: 55, Pages: 942-953, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 6
Tai YF, Hoshi R, Brignell CM, et al., 2011, Persistent Nigrostriatal Dopaminergic Abnormalities in Ex-Users of MDMA ('Ecstasy'): An <SUP>18</SUP>F-Dopa PET Study, NEUROPSYCHOPHARMACOLOGY, Vol: 36, Pages: 735-743, ISSN: 0893-133X
- Author Web Link
- Cite
- Citations: 18
Politis M, Pavese N, Tai YF, et al., 2011, Microglial activation in regions related to cognitive function predicts disease onset in Huntington's Disease: A multimodal imaging study, HUMAN BRAIN MAPPING, Vol: 32, Pages: 258-270, ISSN: 1065-9471
- Author Web Link
- Cite
- Citations: 147
Tai YF, Kullmann DM, Howard RS, et al., 2010, Central nervous system histoplasmosis in an immunocompetent patient, JOURNAL OF NEUROLOGY, Vol: 257, Pages: 1931-1933, ISSN: 0340-5354
- Author Web Link
- Cite
- Citations: 7
Tomasi G, Bertoldo A, Cobelli C, et al., 2010, Use of the global-two-stage algorithm to improve parametric maps in PET imaging: Application to [11C](R)-PK11195, 8th International Symposium on Functional Neuroreceptor Mapping of the Living Brain, Publisher: ACADEMIC PRESS INC ELSEVIER SCIENCE, Pages: S215-S215, ISSN: 1053-8119
Pavese N, Politis M, Tai YF, et al., 2010, Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers, NEUROBIOLOGY OF DISEASE, Vol: 37, Pages: 356-361, ISSN: 0969-9961
- Author Web Link
- Cite
- Citations: 44
Politis M, Pavese N, Tai YF, et al., 2008, Hypothalamic involvement in Huntingtons disease: an <i>in vivo</i> PET study, BRAIN, Vol: 131, Pages: 2860-2869, ISSN: 0006-8950
- Author Web Link
- Cite
- Citations: 131
Reuter I, Tai YF, Pavese N, et al., 2008, Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease, JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol: 79, Pages: 948-951, ISSN: 0022-3050
- Author Web Link
- Cite
- Citations: 88
Edison P, Archer HA, Gerhard A, et al., 2008, Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study, Neurobiology of Disease
Tai YF, 2008, Visualizing out-of-body experience in the brain, NEW ENGLAND JOURNAL OF MEDICINE, Vol: 358, Pages: 855-855, ISSN: 0028-4793
Greyson B, Parnia S, Fenwick P, 2008, Visualizing out-of-body experience in the brain., N Engl J Med, Vol: 358, Pages: 855-856
Tai YF, Pavese N, Gerhard A, et al., 2007, Microglial activation in presymptomatic Huntington's disease gene carriers, BRAIN, Vol: 130, Pages: 1759-1766, ISSN: 0006-8950
- Author Web Link
- Cite
- Citations: 311
Anderson AN, Pavese N, Edison P, et al., 2007, A systematic comparison of kinetic modelling methods generating parametric maps for [<SUP>11</SUP>C]-(R)-PK11195, NEUROIMAGE, Vol: 36, Pages: 28-37, ISSN: 1053-8119
- Author Web Link
- Cite
- Citations: 26
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.